false
0000868278
0000868278
2023-12-28
2023-12-28
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): December 28, 2023
PROPHASE
LABS, INC.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
000-21617 |
|
23-2577138
|
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
No.) |
711
Stewart Avenue, Suite 200
Garden
City, New York |
|
11530 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (215) 345-0919
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any
of the following provisions (see General Instruction A.2. below):
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
Registered Pursuant to Section 12(b) of the Exchange Act:
| Title
of Each Class |
|
Trading
Symbol |
|
Name
of Each Exchange on Which Registered |
| Common
Stock, par value $0.0005 |
|
PRPH |
|
Nasdaq
Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
Chief
Operating Officer
On
January 4, 2024, ProPhase Labs, Inc. (the “Company”) announced that Jed A. Latkin has been appointed to serve as Chief Operating
Officer of the Company, effective on January 1, 2024.
Jed
A. Latkin served as a director and Chief Executive Officer of Navidea Biopharmaceuticals, Inc. (“Navidea”) from October 2018
until October 2021 and as Chief Operating Officer and Chief Financial Officer of Navidea from May 2017 to October 2018.
Mr. Latkin also served as Interim Chief Operating Officer of Navidea from April 2016 to April 2017. Mr. Latkin has more than twenty eight
years of experience in the financial industry supporting many investments in major markets. including biotechnology and pharmaceuticals.
He most recently was employed by Nagel Avenue Capital, LLC since 2010, and in that capacity he provided contracted services as a Turnaround
Specialist for numerous companies and asset management firms. Mr. Latkin was responsible for a large diversified portfolio
of asset-based investments in varying industries, including product manufacturing, agriculture, energy, and healthcare. In connection
with this role, he served as Chief Executive Officer of End of Life Petroleum Holdings, LLC and Black Elk Energy, LLC, Chief Financial
Officer of Viper Powersports, Inc. and West Ventures, LLC, and Portfolio Manager of Precious Capital, LLC. Mr. Latkin previously
served on the Board of Directors for Navidea from October 2018 until October 2021, CORAR from October 2018 until October 2021, Viper
Powersports, Inc. from 2012 to 2013, and the Renewable Fuels Association and Buffalo Lake Advanced Biofuels. Mr. Latkin worked
for over ten years in Investment Banking at Citigroup, Morgan Stanley, and Fleet Boston Robertson Stephens. He also spent five
years as a Co-Portfolio Manager for ING Investment Management. Mr. Latkin earned a B.A. from Rutgers University and a M.B.A. from Columbia
Business School.
On
December 28, 2023, Mr. Latkin accepted the Company’s Offer and Terms of Employment (the “Latkin Offer Letter”), which
provides that Mr. Latkin’s annual base compensation in connection with his service as Chief Operating Officer of the Company will
be $350,000. He will also be entitled to a sign-on bonus in the amount of $80,000. In addition, as an inducement to his employment as
Chief Operating Officer of the Company, the Company granted Mr. Latkin stock options (the “Options”) to purchase up to 500,000
shares of the Company’s common stock, with an exercise price of $6.00 per share and will be exercisable for a period
of seven years, pursuant to an inducement option award agreement to be entered into between the Company and Mr. Latkin. This award
was made in accordance with the employment inducement award exemption provided by Nasdaq Rule 5635(c)(4) and was therefore not awarded
under the Company’s stockholder approved equity plan. The Options will vest over a three-year period, with 25% of the Options vested
at the time of grant and the remainder of the Options vesting ratably on each of the first three anniversaries of the commencement date
of his employment and subject to continued service on each vesting date. Mr. Latkin will be eligible for an annual discretionary bonus
based on both the performance of the Company and of Mr. Latkin, individually. Mr. Latkin will also be eligible to participate in any
and all benefit plans of the Company that are made generally available to similarly-situated employees of the Company.
In
connection with Mr. Latkin’s appointment as Chief Operating Officer the Company, Mr. Latkin will enter into the Company’s
standard form of indemnification agreement, a copy of which was filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K
filed with the Securities and Exchange Commission on August 19, 2009 and is incorporated herein by reference. Pursuant to the terms of
this agreement, the Company may be required, among other things, to indemnify Mr. Latkin for certain expenses, including attorneys’
fees, judgments, fines and settlement amounts incurred by him in any action or proceeding arising out of his service as principal accounting
officer.
There
are no family relationships between Mr. Latkin and any of the officers or directors of the Company, and there are no related party transactions
with Mr. Latkin that are reportable under Item 404(a) of Regulation S-K.
Chief
Financial Officer and Controller
On
December 28, 2023, the Company and Robert A. Morse mutually agreed that Mr. Morse would cease to be Chief Financial Officer of the Company and resume his
role as Controller of the Company, effective January 1, 2024, reporting to the Chief Operating Officer of the Company.
The
foregoing summary of the Latkin Offer Letter does not purport to be a complete description and is qualified
in its entirety by reference to the full text of the Latkin Offer Letter, which is included as Exhibit 10.1 hereto
and incorporated herein by reference.
Item
7.01 Regulation FD Disclosure.
A
copy of the Company’s press release dated January 4, 2024, relating to the announcement described in Item 5.02, is furnished as
Exhibit 99.1 to this Form 8-K.
The
information contained in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section,
nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange
Act, except as expressly set forth by specific reference in such a filing.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
|
* Certain portions
of this Exhibit have been omitted pursuant to Regulation S-K Item 601(a)(6) promulgated under the Exchange Act. The Company agrees
to furnish supplementally a copy of any omitted schedule to the Securities and Exchange Commission upon request. |
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
| |
ProPhase
Labs, Inc. |
| |
|
|
| |
By: |
/s/
Ted Karkus |
| |
|
Ted
Karkus |
| |
|
Chairman
of the Board and Chief Executive Officer |
Date:
January 4, 2024
Exhibit
10.1
CERTAIN
PERSONALLY IDENTIFIABLE INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT PURSUANT TO ITEM 601(A)(6) OF REGULATION S-K. [***] INDICATES
THAT INFORMATION HAS BEEN REDACTED.
December
27, 2023
Jed
Latkin
[***]
Offer
and Terms of Employment
Dear
Jed:
It
is with great pleasure that I offer you a position with ProPhase Labs, Inc. (“ProPhase”) as Chief Operating Officer (“COO”).
You will be reporting directly to Ted Karkus, CEO of ProPhase. We at ProPhase work closely together in a hands-on, team oriented, collaborative
environment. We are developing a high energy environment for the quick thinking, skilled, and professional who are looking to expand
our genomics business, our biopharmaceuticals business, our Pharmaloz Lozenge manufacturing business, and our company as a whole.
Your
position will be, as with all Associates, on an “at will” basis. Assuming acceptance of the terms outlined below, I look
forward to your starting January 1, 2024. The following outlines the terms discussed:
| |
● |
Your
position will be considered a full-time position. |
| |
|
|
| |
● |
Your
compensation will be a base salary of $350,000 per annum. |
| |
|
|
| |
● |
Your
signing bonus will be $80,000 vesting upon the signing of this agreement and payable by January 31, 2024. |
| |
|
|
| |
● |
You
will receive a stock option grant to purchase 500,000 shares of ProPhase Labs common stock at $6 per share subject to Nasdaq rules
and upon executing our standard form of stock option agreement containing the specific terms and conditions of the stock option grant
(25% vested at grant date, 25% per year vesting thereafter over 3 years subject to continued service on each such vesting date). |
| |
|
|
| |
● |
You
will be eligible for an annual bonus based on both company and individual performance to be paid at the discretion of the compensation
committee of the board of directors. |
| |
|
|
| |
● |
You
will be eligible for additional stock options at the discretion of the compensation committee. |
711 Stewart
Ave, Suite 200 · Garden City, NY 11530
· U.S.A
Telephone:
516-464-6121 · Fax: 516-464-6132 ·
For information: www.ProPhaseLabs.com
| |
● |
You
will receive a $900 a month auto allowance. |
| |
|
|
| |
● |
You
will be paid the base salary every other Friday, 26 paychecks annually, subject to all Federal, State and Local tax, withholdings. |
| |
|
|
| |
● |
You
will be eligible for participation in our various employee benefit plans based upon the terms of each of the individual plan provisions. |
| |
|
|
| |
● |
You
will receive 3 paid weeks’ vacation for each 12 months employment in addition to all other scheduled holidays in accordance
with Prophase’s policy. |
| |
|
|
| |
● |
All
out of pocket expenses such as but not limited to business meals, travel and lodging, shall be reimbursed to you in a timely fashion
subject to company policy. |
| |
|
|
| |
● |
During
your employment with the Company, you shall at all times: (i) comply with the terms and conditions set forth in this letter; (ii)
perform and carry out such responsibilities, duties, and authorities as the company may direct, designate, request of, or assign
to you from time to time; (iii) devote sufficient time, attention, effort, and skill to your position with and the business of the
company; and (vi) comply with and abide by the company’s policies, practices, and procedures (as may be amended or otherwise
modified from time to time). |
On
behalf of the company, I am pleased to extend this offer to you. This offer will expire on December 31, 2023 and is conditioned on a
standard background check. I look forward to a long relationship and believe you can become an important component and member of our
team to achieve success. If you have any questions, please feel free to contact me at your earliest convenience.
I
look forward to your favored reply.
| Sincerely, |
|
| |
|
| /s/
Ted Karkus |
|
| |
|
| Ted
Karkus |
|
| Chief
Executive Officer |
|
| Offer
Accepted: |
/s/
Jed Latkin |
| |
|
| Date:
|
12/28/2023 |
Exhibit
99.1
ProPhase
poised to ramp up growth at Pharmaloz and Nebula Genomics in 2024
Company
also plans to commercialize its BE-Smart Esophageal Cancer Test in 2024
Company
announces the hiring of long-time industry veteran Jed Latkin as COO to help build and manage this growth
Garden
City, NY – January 04, 2024 (GLOBE NEWSWIRE) – ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the
“Company”), a next generation biotech, genomics, therapeutics and diagnostics company, today reported that Jed Latkin, a
long-time operations and finance expert, has accepted the role as COO of the parent company.
Mr.
Latkin, a Columbia MBA, represented the seller in the Company’s acquisition of the BE-SMART Esophageal Cancer Test. He immediately
became a consultant to ProPhase to help develop its biotech assets including the BE-Smart test as the Company works toward its commercialization,
as well as work on the Company’s other subsidiaries.
Mr.
Latkin has been in the finance and management industry since 1996 and has worked with over 15 pharmaceutical companies over the last
ten years alone. He has served as CEO, CFO or COO of multiple companies in Biotech, manufacturing, and other verticals.
Mr.
Latkin has also served as a board member of several key industry groups that has allowed him to build a diverse network of contacts that
will help ProPhase find key partnerships over the next several years. In his role at ProPhase he will not only serve as COO of the Company
but also as the head of the newly restructured finance department.
“ProPhase
has successfully transformed itself once again from a company that was mainly focused on the covid testing lab business, into a diversified
manufacturing, biotech and genomics powerhouse that has multi-billion-dollar potential,” said Ted Karkus, CEO of ProPhase Labs.
“We
anticipate an acceleration in growth at both Nebula Genomics and Pharmaloz Manufacturing, as well as commercialization of our BE-SMART
esophageal cancer test, during 2024. Our entire senior team at ProPhase has worked very closely with Jed over the past year and our Board
of Directors has spent meaningful time with him as well. Given our multiple high growth prospects in 2024, we felt that it was the perfect
time to hire him as our COO, to help develop and grow these subsidiaries. With his diversified background at a multitude of companies
spanning from biotech to manufacturing, he is an ideal fit for this multi-faceted COO role,” Mr. Karkus concluded.
Inducement
Award
Mr.
Latkin was awarded a stock option to purchase up to 500,000 shares of the Company’s common stock as an inducement to his employment
as Chief Operating Officer of the Company. This award was made in accordance with the employment inducement award exemption provided
by Nasdaq Rule 5635(c)(4) and was therefore not awarded under the Company’s stockholder approved equity plan. The option award
will vest over a three-year period, with 25% vesting at the time of grant and 25% vesting every twelve months following the commencement
date of his employment, contingent upon his continued service through each vesting date. The options have an exercise price of $6.00
per share and will be exercisable for a period of seven years.
About
ProPhase Labs
ProPhase
Labs, Inc. (Nasdaq: PRPH) is a next-generation biotech, genomics, therapeutics and diagnostics company. Our goal is to create a healthier
world with bold action and the power of insight. We’re revolutionizing healthcare with industry-leading Whole Genome Sequencing
solutions, while developing potential game changer diagnostics and therapeutics in the fight against cancer. This includes a potentially
life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms
of action. Our world-class CLIA labs and cutting-edge diagnostic technology provide wellness solutions for healthcare providers and consumers.
We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed
to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs’ valuable subsidiaries,
their synergies, and significant growth underscores our multi-billion dollar potential.
Forward
Looking Statements
Except
for the historical information contained herein, this document contains forward looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements regarding our strategy, plans, objectives and initiatives, including our
plans to grow our subsidiaries and commercialize our BE-Smart Esophageal Cancer Test in 2024. Management believes that these forward-looking
statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties,
and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. These risks
and uncertainties include but are not limited to our ability to obtain and maintain necessary regulatory approvals, general economic
conditions, consumer demand for our products and services, challenges relating to entering into and growing new business lines, the competitive
environment, and the risk factors listed from time to time in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and any
other SEC filings. The Company undertakes no obligation to update forward-looking statements except as required by applicable securities
laws. Readers are cautioned that forward-looking statements are not guarantees of future performance and are cautioned not to place undue
reliance on any forward-looking statements.
For
more information, visit www.ProPhaseLabs.com.
ProPhase
Media Relations and Institutional Investor Contact:
ProPhase
Labs, Inc.
267-880-1111
investorrelations@prophaselabs.com
ProPhase
Retail Investor Relations Contact:
Renmark
Financial Communications
John
Boidman
514-939-3989
Jboidman@renmarkfinancial.com
Source:
ProPhase Labs, Inc.
v3.23.4
Cover
|
Dec. 28, 2023 |
| Cover [Abstract] |
|
| Document Type |
8-K
|
| Amendment Flag |
false
|
| Document Period End Date |
Dec. 28, 2023
|
| Entity File Number |
000-21617
|
| Entity Registrant Name |
PROPHASE
LABS, INC.
|
| Entity Central Index Key |
0000868278
|
| Entity Tax Identification Number |
23-2577138
|
| Entity Incorporation, State or Country Code |
DE
|
| Entity Address, Address Line One |
711
Stewart Avenue
|
| Entity Address, Address Line Two |
Suite 200
|
| Entity Address, Address Line Three |
G
|
| Entity Address, City or Town |
arden
City
|
| Entity Address, State or Province |
NY
|
| Entity Address, Postal Zip Code |
11530
|
| City Area Code |
(215)
|
| Local Phone Number |
345-0919
|
| Written Communications |
false
|
| Soliciting Material |
false
|
| Pre-commencement Tender Offer |
false
|
| Pre-commencement Issuer Tender Offer |
false
|
| Title of 12(b) Security |
Common
Stock, par value $0.0005
|
| Trading Symbol |
PRPH
|
| Security Exchange Name |
NASDAQ
|
| Entity Emerging Growth Company |
false
|
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 2 such as Street or Suite number
| Name: |
dei_EntityAddressAddressLine2 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 3 such as an Office Park
| Name: |
dei_EntityAddressAddressLine3 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
ProPhase Labs (NASDAQ:PRPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
ProPhase Labs (NASDAQ:PRPH)
Historical Stock Chart
From Apr 2023 to Apr 2024
